Austria Manuel Reiberg, president of the Forum of the Research-Based Pharmaceutical Industry in Austria (FOPI), which represents the 27 leading pharmaceutical innovators in Austria focused on pharmaceutical innovation, discusses the struggles facing drug innovation under the new reimbursement system, as well as the steps that must be taken to bolster the…
Austria Herwig Ostermann, executive director of the Austrian Public Health Institute (GOeG), a neutral entity that brings expertise and evidence together to help plan and promote Austrian healthcare, provides insights into the sorts of reforms that the country is going through to create a more sustainable, enduring and efficient system. Could…
Austria Dr. Erwin Klein, CEO and co-founder of easypharm, a generics and OTC company founded by Austrians for Austria, provides an overview of his exciting entrepreneurial experience and the challenges associated with establishing a new pharmaceutical company in Austria as well as his expert view on the current healthcare system. He…
Austria Ana Kostova, Austrian country president for AstraZeneca, a global powerhouse in innovative drugs and R&D, discusses the opportunities and challenges of introducing innovative treatments into the Austrian healthcare system as well as AstraZeneca´s exciting pipeline, especially in the field of oncology. She also provides an insight into the future potential…
Austria Dr. Christoph Zielinski, head of the organizational unit of the Comprehensive Cancer Center of Vienna (CCC), a representative of the Austrian oncological community, provides an insight into the key activities of the center. He also gives an overview of the current state of the Austrian healthcare and oncology ecosystem as…
Austria Harald Isemann, chairman of the Vienna Biocenter (VBC) – one of the leading life science hubs in Europe – and Managing Director of the Institute of Molecular Pathology (IMP), a VBC member, provides insights into the main tasks of the VBC, the organization of the IMP and the challenges it…
Pharma PharmaBoardroom’s readers were polled on what they felt was the most disruptive force in the pharmaceutical industry today. Possible answers were big data and digitalization, patient-centricity, economic austerity, and advancements in supply chain management. Big Data and Digitalization Overall, most respondents chose big data and digitalization (34 percent) and economic…
Austria Dr. Andreas Windischbauer, president of the Austrian Association of Full-Line Pharmaceutical Wholesalers (PHAGO) discusses the organization’s role within the Austrian pharma industry, its current challenges, price pressures, competition, and future prospects. Can you give us a brief overview of PHAGO? “We live in a changing world with a lot of…
USA In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The eight oncology treatments approved by the FDA this year represent…
Japan Kenichi Tamiya, director for Biomedical Policy at the Kobe City Government and managing director of the Kobe Foundation for Biomedical Research and Innovation (FBRI), discusses the central Japanese city of Kobe’s significant potential as a cutting-edge R&D hub for both the national and global life science industries. “Alongside promoting translational…
Algeria Algeria’s key macroeconomic and healthcare indicators. Cardiovascular disease prevalence in North Africa. Diabetes prevalence in North Africa. The rate of change in the number of years of healthy life lost to obesity in Africa. Click here to download the latest roundtable discussion on Algerian healthcare.
USA Rolando Pablos, Secretary of State of Texas, discusses Texas’s unique business-friendly environment, the significance of the life sciences sector to the state’s economy (which would be the tenth largest in the world were Texas a country), innovation, and internationalization. Across the board we are industry agnostic, meaning that whatever…
See our Cookie Privacy Policy Here